[MOL] Re: ABSTRACTS-SOMETHING FOR EVERYONE! [01261] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] Re: ABSTRACTS-SOMETHING FOR EVERYONE!
















SAFETY AND EFFICACY OF ANTIESTROGENS FOR PREVENTION OF BREAST CANCER
> | Explore the rationale for clinical trials, recent findings, and
potential
> | concerns with antiestrogens.
> | Am J Health-Syst Pharm 57(14):1315-1322, 2000
> | http://oncology.medscape.com/25676.rhtml
> | <a href="http://oncology.medscape.com/25676.rhtml">Read it Here</a>
> |
> | CONTEMPORARY MANAGEMENT OF SUPERFICIAL BLADDER CANCER
> | Review the indications for the use of intravesical agents as well as
their
> | efficacy, toxicity, and cost.
> | Cancer Control; JMCC 7(4):335-339, 2000.
> | http://oncology.medscape.com/25703.rhtml
> | <a href="http://oncology.medscape.com/25703.rhtml">Read it Here</a>
> |
> | BLADDER-SPARING TREATMENT OF INVASIVE BLADDER CANCER
> | Explore alternative techniques to radical cystectomy with pelvic lymph
> node
> | dissection, the standard treatment for patients with invasive bladder
> | cancer.
> | Cancer Control; JMCC 7(4):340-346, 2000.
> | http://oncology.medscape.com/25715.rhtml
> | <a href="http://oncology.medscape.com/25715.rhtml">Read it Here</a>
> |
> | MONOCLONAL ANTIBODY-DIRECTED CYTOTOXIC THERAPY PROVIDES HOPE FOR THE
> FUTURE
> | Find out about this tumor-targeted approach, currently undergoing phase
> III
> | trials.
> | Drugs and Ther Perspect 16(2):5-7, 2000
> | http://oncology.medscape.com/25704.rhtml
> | <a href="http://oncology.medscape.com/25704.rhtml">Read it Here</a>
> |
> | MULTIPLE MYELOMA: GUARDING AGAINST INFECTION
> | Prophylactic regimens can reduce morbidity and mortality in myeloma
> | patients, but only a more structured analysis can determine long-term
> | efficacy.
> | Infect Med 17(7):500-504, 2000
> | http://oncology.medscape.com/25712.rhtml
> | <a href="http://oncology.medscape.com/25712.rhtml">Read it Here</a>
> |
> | ASK THE EXPERTS - TREATMENT OF OLIGOMETASTATIC MEDULLARY CARCINOMA OF
THE
> | THYROID?
> | I am following up a 40-year-old female with metastatic medullary
carcinoma
> | of the thyroid.
> | http://oncology.medscape.com/25668.rhtml
> | <a href="http://oncology.medscape.com/25668.rhtml">Read it Here</a>
> |
> | ASK THE EXPERTS - HOW TO DOWNSTAGE AN INOPERABLE RECTOSIGMOID
> ADENOCARCINOMA?
> | What would be a reasonable chemotherapy regimen to downstage a patient,
> | considering that newer drugs such as irinotecan and oxaliplatin are now
> | available and that the response rates may be only 30% to 40%?
> | http://oncology.medscape.com/25687.rhtml
> | <a href="http://oncology.medscape.com/25687.rhtml">Read it Here</a>
> |
> | ASK THE EXPERTS - MANAGEMENT OF METASTATIC OVARIAN CANCER IN A PATIENT
> WITH
> | RENAL IMPAIRMENT?
> | A 64-year-old female, diagnosed with metastatic ovarian cancer 2 years
> ago,
> | achieved complete remission after treatment with carboplatin-paclitaxel.
> | http://oncology.medscape.com/25714.rhtml
> | <a href="http://oncology.medscape.com/25714.rhtml">Read it Here</a>
> |

> |
> | MEDICARE'S EFFORTS TO REDUCE DRUG PAYMENTS PREDICTED TO HURT CANCER
> PATIENTS
> | Cancer-care specialists are awaiting word from the federal government on
> | Medicare's plan to reduce payment rates for dozens of reimbursable
> | prescription drugs.
> | http://oncology.medscape.com/25647.rhtml
> | <a href="http://oncology.medscape.com/25647.rhtml">Read it Here</a>
> |
> | UK ONCOLOGISTS CAMPAIGN FOR NATIONAL CANCER INSTITUTE
> | UK oncologists are calling on the public to pressure the government into
> | establishing a national cancer institute in Britain, which has the worst
> | cancer survival rate in Europe.
> | http://oncology.medscape.com/25556.rhtml
> | <a href="http://oncology.medscape.com/25556.rhtml">Read it Here</a>
> |
> | IOM OUTLINES STEPS NEEDED TO ENSURE PRIVACY OF RESEARCH SUBJECTS
> | The Institute of Medicine (IOM) of the National Academy of Sciences has
> | recommended several steps for sponsors of clinical research and
> | institutional review boards to take in order to protect the privacy of
> | patients' medical records.
> | http://oncology.medscape.com/25641.rhtml
> | <a href="http://oncology.medscape.com/25641.rhtml">Read it Here</a>
> |
> | PHASE III TRIALS OF PRINOMASTAT IN ADVANCED CANCERS DISCONTINUED BUT
> | MULTIPLE PHASE II TRIALS CONTINUE
> | Pfizer has announced that preliminary results of phase III clinical
trials
> | of prinomastat, a matrix metalloprotease inhibitor (MMPI) in advanced
> | hormone refractory prostate cancer and advanced (stage IV) non-small
cell
> | lung cancer did not meet primary efficacy objectives.
> | http://oncology.medscape.com/25682.rhtml
> | <a href="http://oncology.medscape.com/25682.rhtml">Read it Here</a>
> |
> | PFIZER ENDS TWO PHASE III CANCER TRIALS DUE TO POOR EFFICACY
> | Pfizer has halted two phase III studies of the matrix metalloprotease
> | inhibitor prinomastat, which the company was investigating as a
potential
> | treatment for advanced hormone-refractory prostate cancer and advanced
> | non-small cell lung cancer.
> | http://oncology.medscape.com/25504.rhtml
> | <a href="http://oncology.medscape.com/25504.rhtml">Read it Here</a>
> |
> | MARKER OF BREAST CANCER, PROSTATE CANCER FOUND IN TEARS
> | A marker protein in tears may indicate whether people have, or are
likely
> | to develop, breast cancer or prostate cancer, according to a
serendipitous
> | finding by a team of Australian scientists.
> | http://oncology.medscape.com/25544.rhtml
> | <a href="http://oncology.medscape.com/25544.rhtml">Read it Here</a>
> |
> | ADDITIONAL BREAST CANCER SUSCEPTIBILITY GENE IDENTIFIED
> | European families that have a mutation in CDKN2A, a multiple tumor
> | suppressor gene, are at increased risk not only for melanoma and
> pancreatic
> | cancer, as has been reported previously, but also for breast cancer.
> | http://oncology.medscape.com/25493.rhtml
> | <a href="http://oncology.medscape.com/25493.rhtml">Read it Here</a>
> |
> | OMEPRAZOLE TREATMENT IN H. PYLORI-INFECTED PATIENTS MAY INCREASE CANCER
> RISK
> | Helicobacter pylori infection increases the degree of acid inhibition
and
> | accompanying changes in the gastric environment induced by omeprazole
> | treatment, which may subsequently increase the risk of mutagenesis and
> | carcinogenesis, according to a report in the August issue of
> | Gastroenterology.
> | http://oncology.medscape.com/25576.rhtml
> | <a href="http://oncology.medscape.com/25576.rhtml">Read it Here</a>
> |
> | IN UTERO ESTROGEN EXPOSURE LINKED TO TESTICULAR GERM-CELL CANCER
> | Prenatal exposure to maternal hormones, especially estrogen, appears to
> | influence subsequent risk of developing testicular germ-cell cancer,
> | according to researchers in Canada and the US.
> | http://oncology.medscape.com/25634.rhtml
> | <a href="http://oncology.medscape.com/25634.rhtml">Read it Here</a>
> |
> | DELIRIUM OFTEN MANAGEABLE IN TERMINAL CANCER PATIENTS
> | While common among terminal cancer patients, delirium is often
treatable,
> | according to a report published in the June issue of the Journal of Pain
> | and Symptom Management.
> | http://oncology.medscape.com/25529.rhtml
> | <a href="http://oncology.medscape.com/25529.rhtml">Read it Here</a>
> |
> | STEM CELL TRANSPLANTATION SHOWS PROMISE FOR TREATING HIV-RELATED NHL
> | Two patients with HIV-related non-Hodgkin's lymphoma (NHL) who were
> treated
> | with autologous stem cell transplantation (ASCT) while concomitantly
> | receiving highly active antiretroviral therapy remained in clinical
> | remission from the lymphoma for at least 20 and 28 months, respectively,
> | researchers report.
> | http://oncology.medscape.com/25573.rhtml
> | <a href="http://oncology.medscape.com/25573.rhtml">Read it Here</a>
> |
> | ANTIMICROBIAL CATHETERS SHOW LONG-TERM, BROAD-SPECTRUM ANTIMICROBIAL
> ACTIVITY
> | Catheters coated with miconazole-rifampicin are active against
> | staphylococci, other gram-positive bacteria, Candida albicans and
various
> | gram-negative bacilli.
> | http://oncology.medscape.com/25503.rhtml
> | <a href="http://oncology.medscape.com/25503.rhtml">Read it Here</a>
> |
> | EARPIECES CUT MOBILE PHONE RADIATION RISK
> | Hands-free mobile phone kits can reduce the effects of electromagnetic
> | radiation from wireless phones by more than 90%, according to Australian
> | study results released on Friday.
> | http://oncology.medscape.com/25509.rhtml
> | <a href="http://oncology.medscape.com/25509.rhtml">Read it Here</a>
> |
> | HANDS-FREE KITS CUT EXPOSURE TO MOBILE PHONE RADIATION
> | Hands-free kits for mobile phones significantly cut the amount of
> radiation
> | that users are exposed to, compared with normal use of mobile phones,
> | according to a British government report released Tuesday.
> | http://oncology.medscape.com/25588.rhtml
> | <a href="http://oncology.medscape.com/25588.rhtml">Read it Here</a>
> |
> | GENTA ANTICANCER COMPOUND GETS ORPHAN DRUG STATUS
> | Genta Corporation said on Monday that the US Food and Drug
Administration
> | has granted the company's lead anticancer compound, Genasense, orphan
drug
> | status for treatment of malignant melanoma.
> | http://oncology.medscape.com/25565.rhtml
> | <a href="http://oncology.medscape.com/25565.rhtml">Read it Here</a>
> |
> | FDA CLEARS NUCLETRON'S SPOT IMAGING SOFTWARE FOR PROSTATE SEED
> IMPLANTATION
> | The US Food and Drug Administration (FDA) has granted market clearance
to
> | Dutch firm Nucletron BV for its Sonographic Planning of Oncology
Treatment
> | (SPOT) software, which aids in permanent seed implantation in
> brachytherapy
> | for prostate cancer.
> | http://oncology.medscape.com/25563.rhtml
> | <a href="http://oncology.medscape.com/25563.rhtml">Read it Here</a>
> |
> | ENGINEERED DENDRITIC CELLS ENHANCE T-CELL RESPONSES
> | Scientists have found that engineering dendritic cells to express higher
> | levels of three co-stimulatory molecules enhances T-cell activation.
> | http://oncology.medscape.com/25521.rhtml
> | <a href="http://oncology.medscape.com/25521.rhtml">Read it Here</a>
> |
> | VEGF MAY BE A SURVIVAL FACTOR FOR TUMOR ENDOTHELIAL CELLS
> | In a murine model of colorectal carcinoma liver metastasis, antibodies
> | targeting vascular endothelial growth factor (VEGF) receptor-2 reduce
> tumor
> | growth by causing endothelial cell death, as well as by inhibiting
> | angiogenesis, Texas researchers report.
> | http://oncology.medscape.com/25606.rhtml
> | <a href="http://oncology.medscape.com/25606.rhtml">Read it Here</a>
> |
> | AGING TELOMERASE-DEFICIENT, P53 HETEROZYGOUS MICE DEVELOP EPITHELIAL
> TUMORS
> | Mice deficient in telomerase and heterozygous for p53 develop epithelial
> | tumors as they age that are similar to those typically found in aging
> | humans, researchers report in the August 10th issue of Nature.
> | http://oncology.medscape.com/25652.rhtml
> | <a href="http://oncology.medscape.com/25652.rhtml">Read











------------------------------------------------------------------------
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------